Mitro Named President & Chief Executive Officer, Readies Pro-ocularTM for Phase 3 Trials The company's breakthrough drug is the first product for Dry Eye Disease (DED) to utilize transappendageal forehead delivery and the only product to treat DED by targeting the ophthalmic branch of the trigeminal nerve. GREENWICH, Conn. , Aug.
13, 2024 /PRNewswire/ -- Spencer Trask & Co . ( Spencer Trask ), the advanced technology development firm, announced today the launch of Signal12 Inc. (Signal12), a clinical-stage dry eye company.
Signal12 is revolutionizing treatments for Dry Eye Disease (DED) and eliminating the hassle of eye drop instillation with its first-of-a-kind, patented technology that enables existing drugs to act through unique neural pathways. Signal12's breakthrough topical drug, Pro-ocular TM, is the first product in eyecare to utilize transappendageal forehead delivery (drug delivery via hair follicles or sweat glands in the skin) and the only product to treat DED by targeting the ophthalmic branch of the trigeminal nerve. Pro-ocular, when applied to the forehead twice daily, has been shown to be safe and effective for DED of all severity levels.
This has been demonstrated through three separate Phase 2 clinical studies . Signal12 licensed the Pro-ocular intellectual property, which included 89 patents that cover 49 countries, from Glia LLC, which is a Spencer Trask venture. Thomas Mitro was recruited by Spencer Trask to lead Signal12 as president and chief executive .